Clinical Trials & Research

Health involves the wellbeing of the physical, emotional, mental, and intellectual domains of man. These are deeply impacted by social factors, often termed the social determinants of health (SDoH). However, these are not documented clearly or adequately in electronic health records (EHRs). Study: Large language models to identify social determinants of health in electronic health records.
0 Comments
The Food and Drug Administration’s unprecedented approval of Florida’s plan to import drugs from Canada was made possible only after Alex Azar, as the Trump administration’s Health and Human Services secretary, certified that bringing medicines over the border could be done safely. Azar made the historic declaration in September 2020, just two months before his
0 Comments
Antibiotic overuse can lead to antibiotic resistance, but classic antibiotic resistance might not completely explain why antibiotics sometimes fail. Sub-populations of bacteria called persister cells are capable of surviving in the presence of lethal doses of antibiotics for prolonged periods. Although persister cells have been intensively researched, evidence linking them to poor patient outcomes has
0 Comments
Cedars-Sinai investigators are using electronic health records to identify hospitalized patients likely to have dementia. The method they developed, detailed in a study published in the peer-reviewed Journal of the American Geriatrics Society, is designed to help medical staff tailor care to best serve these patients. People with dementia or cognitive impairment can be especially
0 Comments
Did smokers do better than non-smokers in a clinical trial for an experimental cancer treatment? That was the intriguing question that led University of Iowa researchers and their colleagues to develop a drinkable, carbon monoxide-infused foam that boosted the effectiveness of the therapy, known as autophagy inhibition, in mice and human cells. The findings were
0 Comments
Taletrectinib also shrank tumors in 57 percent of people with ROS1-positive NSCLC who had previously been treated with a ROS1 TKI in the trial Taletrectinib continues to be generally well tolerated with low incidence of neurological adverse events Interim TRUST-II results are consistent with data previously reported from TRUST-I trial NEW YORK, NY, October 21,
0 Comments
After endocrine therapy, the most common prior treatments for patients in the datopotamab deruxtecan and chemotherapy arms, respectively, included one (63%, 61%) to two (37%, 38%) lines of chemotherapy and CDK4/6 inhibitor inhibitors (82%, 78%). At the 17 July 2023 data cut-off, 93 patients remained treatment with datopotamab deruxtecan and 39 remained on chemotherapy. AstraZeneca
0 Comments
MADRID, October 23, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 MARIPOSA study showing RYBREVANT® (amivantamab-vmjw) in combination with lazertinib compared to osimertinib resulted in a 30 percent reduction in the risk of disease progression or death (Hazard Ratio [HR]=0.70; 95 percent Confidence Interval [CI], 0.58–0.85;
0 Comments
MADRID, October 23, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 MARIPOSA-2 study showing the regimen of RYBREVANT® (amivantamab-vmjw) given with or without lazertinib and combined with chemotherapy reduced the risk of disease progression or death by 56 and 52 percent respectively (Hazard Ratio [HR]=0.44; 95
0 Comments
IRVINE, Calif., Oct. 24, 2023 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 multicenter, randomized, double-blind, placebo-controlled studies evaluated the safety and efficacy of
0 Comments
TROPION-Lung05 resultsInitial results from the TROPION-Lung05 Phase II trial showed datopotamab deruxtecan demonstrated encouraging antitumour activity in patients with heavily pretreated locally advanced or metastatic NSCLC with actionable genomic alterations including those with EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements. These data were presented at the ESMO 2023 Congress on Saturday, 21 October (1314MO).
0 Comments
mRNA-1083 is Moderna’s first respiratory combination vaccine candidate to enter a Phase 3 trial Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company has multiple programs in Phase 3 development across several
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE) Oct 24, 2023 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a devastating, life-threatening illness. Currently, there is only
0 Comments